Anna Pasetto
Overview
Explore the profile of Anna Pasetto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
3229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Silva D, Chrobok M, Rovesti G, Healy K, Wagner A, Maravelia P, et al.
Front Immunol
. 2022 Jul;
13:896242.
PMID: 35784320
Cellular immunotherapies based on T cell receptor (TCR) transfer are promising approaches for the treatment of cancer and chronic viral infections. The discovery of novel receptors is expanding considerably; however,...
12.
Maravelia P, Silva D, Rovesti G, Chrobok M, Stal P, Lu Y, et al.
Cancers (Basel)
. 2021 Sep;
13(17).
PMID: 34503144
Hepatocellular carcinoma (HCC) is one of the deadliest cancer types worldwide. HCC is often diagnosed at a late stage when the therapeutic options are very limited. However, even at the...
13.
Pasetto A, Lu Y
Front Immunol
. 2021 Jun;
12:689091.
PMID: 34163487
T cells have been known to be the driving force for immune response and cancer immunotherapy. Recent advances on single-cell sequencing techniques have empowered scientists to discover new biology at...
14.
Paria B, Levin N, Lowery F, Pasetto A, Deniger D, Parkhurst M, et al.
J Immunother
. 2020 Oct;
44(1):1-8.
PMID: 33086340
Engineered T cells expressing tumor-specific T-cell receptors (TCRs) are emerging as a mode of personalized cancer immunotherapy that requires identification of TCRs against the products of known driver mutations and...
15.
Pasetto A
Cancers (Basel)
. 2020 Oct;
12(10).
PMID: 33007884
In the recent years, immunotherapy has achieved impressive results utilizing different approaches, from (chimeric antigen receptor) CAR-T cells directed against CD19 for the treatment of leukemia and lymphomas to the...
16.
Chronic Viral Liver Diseases: Approaching the Liver Using T Cell Receptor-Mediated Gene Technologies
Healy K, Pasetto A, Sobkowiak M, Soon C, Cornberg M, Aleman S, et al.
Cells
. 2020 Jun;
9(6).
PMID: 32560123
Chronic infection with viral hepatitis is a major risk factor for liver injury and hepatocellular carcinoma (HCC). One major contributing factor to the chronicity is the dysfunction of virus-specific T...
17.
Sallberg M, Pasetto A
Front Immunol
. 2020 Apr;
11:552.
PMID: 32292409
Liver cancer is the third most common cause of cancer related death in the World. From an epidemiological point of view the risk factors associated to primary liver cancer are...
18.
Maravelia P, Frelin L, Ni Y, Caro Perez N, Ahlen G, Jagya N, et al.
J Infect Dis
. 2020 Jan;
223(1):128-138.
PMID: 31994701
Background: Chronic hepatitis B and D virus (HBV/HDV) infections can cause cancer. Current HBV therapy using nucleoside analogues (NAs) is life-long and reduces but does not eliminate the risk of...
19.
Gros A, Tran E, Parkhurst M, Ilyas S, Pasetto A, Groh E, et al.
J Clin Invest
. 2019 Oct;
129(11):4992-5004.
PMID: 31609250
Tumor-resident lymphocytes can mount a response against neoantigens expressed in microsatellite-stable gastrointestinal (GI) cancers, and adoptive transfer of neoantigen-specific lymphocytes has demonstrated antitumor activity in selected patients. However, whether peripheral...
20.
Pasetto A, Ahlen G, Sallberg M
Aliment Pharmacol Ther
. 2019 Oct;
50(8):963-964.
PMID: 31591767
No abstract available.